Bill Text: TX HB4014 | 2025-2026 | 89th Legislature | Engrossed

Texas House Bill 4014

Bill Title: Relating to a study on the use of psychedelic therapies in the treatment of certain conditions.

Sponsorship: Bipartisan Bill

Status: (Engrossed - Dead) 2025-05-19 - Referred to Health & Human Services [HB4014 Detail]

Download: Texas-2025-HB4014-Engrossed.html



	By: Bucy, Oliverson, Pierson, Romero, et al.	H.B. No. 4014



	A BILL TO BE ENTITLED
	AN ACT
	relating to a study on the use of psychedelic therapies in the
	treatment of certain conditions.
	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
	SECTION 1. (a) In this Act:
	(1) "Commission" means the Health and Human Services
	Commission.
	(2) "Psychedelic therapies" means the use of
	3,4-methylenedioxymethamphetamine (MDMA), psilocybin, or ketamine
	to treat mental health or other medical conditions.
	(b) The commission, in consultation with Baylor College of
	Medicine and the Center for Psychedelic Research and Therapy at
	Dell Medical School at The University of Texas at Austin, shall
	conduct a study on the use of psychedelic therapies for treatment of
	post-traumatic stress disorder, depression, and other co-occurring
	conditions.
	(c) In conducting the study, the commission shall:
	(1) review clinical trials on the efficacy of using
	psychedelic therapies in the treatment of post-traumatic stress
	disorder, depression, and other co-occurring conditions;
	(2) review current literature regarding the use of
	psychedelic therapies in the treatment of post-traumatic stress
	disorder, depression, and other co-occurring conditions;
	(3) review actions of the United States Food and Drug
	Administration regarding psychedelic therapies for treatment of
	post-traumatic stress disorder, depression, and other co-occurring
	conditions;
	(4) evaluate treatment guidelines for use of
	psychedelic therapies to treat post-traumatic stress disorder,
	depression, and other co-occurring conditions and recommend
	guidelines and best practices for providers; and
	(5) evaluate patient access to current treatment for
	post-traumatic stress disorder, depression, and other co-occurring
	conditions and recommend legislative or other actions necessary to
	ensure patient access to psychedelic therapies following approval
	by the United States Food and Drug Administration, including
	considerations of provider availability, affordability,
	accessibility, training and licensure, and other regulatory
	requirements.
	(d) In addition to any money appropriated by the
	legislature, the commission may solicit and accept federal funds
	and gifts, grants, or donations from any source to administer and
	finance the study conducted under this section.
	(e) Not later than December 1, 2026, the commission shall
	submit to the governor, the lieutenant governor, the speaker of the
	house of representatives, and the chair of the standing committee
	of each house of the legislature with primary jurisdiction over the
	commission a written report that includes:
	(1) the results of the study conducted under this
	section; and
	(2) any recommendations for legislative or other
	action necessary to ensure patient access to psychedelic therapies
	for treatment of post-traumatic stress disorder, depression, and
	other co-occurring conditions after those therapies are approved by
	the United States Food and Drug Administration.
	(f) This Act expires September 1, 2027.
	SECTION 2. The Health and Human Services Commission is
	required to implement a provision of this Act only if the
	legislature appropriates money specifically for that purpose. If
	the legislature does not appropriate money specifically for that
	purpose, the commission may, but is not required to, implement a
	provision of this Act using other money available for that purpose.
	SECTION 3. This Act takes effect September 1, 2025.